The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


Eisai and Halozyme to evaluate combination drug for treatment of metastatic breast cancer.....           Ligand licenses Captisol to Sanofi for development of MET kinase inhibitor.....           AbbVie's Humira gets European approval to treat hidradenitis suppurativa.....           Pediatric cancer treatment based on Nanosmart platform obtains FDA's orphan drug status.....           Juno IND application given FDA nod for leukemia drug candidate JCAR015.....           Ferrer completes second Phase III trial of impetigo treatment ozenoxacin.....           Neos resubmits ADHD drug application for FDA review.....           KaloBios' IND application for KB003 gets FDA clearance to treat patients with CMML.....           Medivir begins Phase I trial of AL-704 to treat hepatitis C.....           GSK bribery allegations crop up in Romania.....           AstraZeneca tops Q2 estimates on strength of diabetes drugs and clot-buster Brilinta.....           Depomed pooh-poohs Horizon's new bid in latest rejection.....           Express Scripts: Pricey PCSK9 drugs poised to 'wreak havoc'.....           With solid Q2, Sanofi CEO says M&A could be part of growth strategy.....           Celgene fights for sanction on patent challenger Bass.....           Eisai's Lenvima gets FDA breakthrough status for renal cell carcinoma.....           FDA accepts ZS Pharma's ZS-9 NDA to treat hyperkalemia.....           Hikma agrees to acquires Roxane Laboratories for $1.18bn.....           Arena begins Phase II trial of APD334 to treat autoimmune diseases.....           CSSi LifeSciences, PRC Clinical partner to provide extended clinical trial services.....           Lightlake partner Adapt Pharma submits NDA to FDA for Narcan nasal spray.....           Sanofi's first Lixilan Phase III trial meets primary endpoint.....           Kyowa Hakko Kirin, Bristol-Myers enter into immuno-oncology clinical collaboration.....           Flexion completes patient enrollment in FX006 Phase III trial for osteoarthritis of the knee.....           KaloBios gets FDA clearance for IND application for KB003 to treat patients with CMML.....           Highland subsidiary Ironshore begins Phase III trial of HLD-200 in pediatric ADHD patients.....           OncoMed begins Phase I trial of anti-RSPO3 antibody.....           FDA grants breakthrough status for Progenics' Azedra to treat pheochromocytoma and paraganglioma.....           EMA confirms successful validation of Teva's reslizumab MAA.....           Regeneron, Sanofi launch new immuno-oncology collaboration.....           Merck improves immuno-oncology portfolio with acquisition of cCAM Biotherapeutics.....           FDA accepts OPKO?s NDA for rayaldee to treat CKD.....           Pfizer drops effort to make Lipitor an OTC med.....           UPDATED: CEO Martin says significant growth lies ahead, as Gilead reports huge quarter.....           Bayer's bets on consumer health deliver during Q2.....           Sanofi looks to go to FDA in Q4 as diabetes combo LixiLan hits goal in trial.....           Glaxo posts 'unremarkable' results in first quarter after Novartis swap.....           Analysts: Mylan won't land Perrigo, even with Teva out of the way.....           Bayer, Sprint Bioscience partner to develop new oncology drug candidates.....           Biogen enters strategic alliance to develop new Parkinson?s disease treatments.....           Boehringer, Hanmi to develop third generation EGFR targeted therapy in lung cancer.....           Pfizer ends OTC Lipitor program after trial fails.....           CHPA welcomes House introduction of DXM Abuse Prevention Act.....           Protecting Access to Pain Relief Coalition launches to ensure Americans have access to trusted pain relief.....           Donaldson and Business Review FREE Webinar Series Offers Specialized Content for Pharma/Healthcare/Packaging/ Food and Beverage Industry Professionals.....           Merck beats Wall Street's expectations with a patchwork of efforts.....           Sanofi's Genzyme agrees to buy AstraZeneca's rare disease therapy Caprelsa for $300m.....           Hikma shells out $2.65B for Boehringer's U.S. generics business.....           Pfizer lifts guidance as Prevnar, Ibrance trigger Q2 beats.....           Hard-hit Biogen needs to act fast, analysts say--or beware its deal-hungry peers.....           Merck beats Wall Street's expectations with a patchwork of efforts.....           Sanofi hands Regeneron $1.8B for new immuno-oncology pact.....           With new cash on its way, it's back to buying for deal-happy Allergan, CEO says.....           Teva agrees to buy Allergan Generics for $40.5bn.....           Bloomage, Medytox set up new JV to jointly develop Botulinum Toxin market in China.....           Invion, Hovione sign joint development and licensing deal for inhaled Zafirlukast.....           MonoSol Rx begins Phase IIa trial for Oral Insulin Film.....           Fresenius Kabi launches Glucagon for injection in US.....           Adapt Pharma submits NDA to FDA for Narcan nasal spray.....           Inovio begins Phase I trial of INO-5150 DNA immunotherapy to treat prostate cancer.....           Vaxin enrolls first patient in Phase I trial of HepTcell to treat hepatitis B virus.....           China's Yabao and Lawson complete discovery validation work of annexin A5-based products.....           DNDi, Takeda to develop new treatment for visceral leishmaniasis.....           Novartis' Odomzo skin cancer drug gets FDA approval.....           Knight Therapeutics to manage regulatory, commercial activities for AzaSite in Canada.....           Allergan agrees to acquire Naurex for $560m.....           Shire gets EMA Committee positive opinion for Intuniv to treat ADHD.....           EyeGate gets USPTO notice of allowance for proprietary dexamethasone phosphate formulation.....           ZIOPHARM gets FDA orphan drug status for Ad-RTS-hIL-12 to treat malignant glioma.....           FDA approves Amgen's Kyprolis for combination use to treat relapsed multiple myeloma.....           Teva Parenteral Medicines begins recall of Select Lots of Adrucil 5g/100mL due to particulate matter.....           Forget Mylan: Teva inks $40B-plus pact for Allergan's generics biz.....           AstraZeneca snags $300M from Sanofi for rare cancer med amid cash-generating deal spree.....           Amgen wins new myeloma nod for blockbuster hopeful Kyprolis.....           Analyst: J&J's Stelara to challenge Novartis in ankylosing spondylitis.....           About that brand/generics hybrid thing? Make that brands only, Allergan says with Teva deal.....           Aegerion dumps CEO who got it into FDA trouble for talking too freely.....           GSK gets EMA Committee positive opinion for its malaria candidate vaccine Mosquirix.....           AbbVie's Technivie gets FDA approval to treat genotype 4 chronic hepatitis C.....           Sanofi and Regeneron's Praluent gets FDA approval to treat high LDL cholesterol in adults.....           Eddingpharm to begin Phase I trial of Brinavess in China.....           EMA accepts Merck's MAA for grazoprevir/elbasvir to treat chronic hepatitis C infection.....           Merck Serono extends collaboration with BioMed X.....           Pulmatrix issued patents covering iSPERSE technology to treat patients with inhaled dry powders.....           Eagle Pharmaceuticals? RTU Bivalirudin NDA accepted for filing by FDA.....           National Pharma Industries introduces new allergy medication Naramin.....           Shire CEO: We're prepared to wait for the right deal.....           Biogen gets beaten up as slowing Tecfidera sales lead it to trim forecast.....           Novartis' newly acquired melanoma combo wins EU recommendation.....           AbbVie falls short on Q2 sales--but don't blame biosimilars, CEO says.....           Cancer docs try to rally public behind plan to fight drug prices.....           UnitedHealth uses newfound scale to negotiate pay-for-performance deals.....           Health Canada approves Theravance's Vibativ for HAP/VAP caused by gram-positive bacteria.....           Amgen submits sNDA to FDA for Kyprolis to treat relapsed multiple myeloma.....           EMA validates Bristol-Myers's two type II variation applications to extend Opdivo indication.....           Lpath gets FDA nod to initiate Phase I lpathomab clinical trial.....           Janssen submits sNDA for Olysio in combination with Sofosbuvir to treat CHC infection.....           TTY Biopharm to market PharmaMar's Aplidin in Taiwan to treat hematological cancers.....           Heron begins second Phase II trial of HTX-011 to treat post-operative pain.....           Eli Lilly's Q2 beats the Street as newer products, animal health buy pitch in.....           RegeneRx gets notice of acceptance for Australian patent for key TB4 peptide fragment.....           Cardiome submits supplemental new drug submission for Aggrastat to Health Canada.....           Acorda awarded grant to study ARCUS Technology in respiratory distress syndrome.....           Tract Therapeutics completes Phase I safety trial using patient?s immune cells to prevent organ rejection.....           Roche clocks fast growth for new meds Perjeta, Esbriet as it girds for biosim rivalries.....           Eli Lilly's Q2 beats the Street as newer products, animal health buy pitch in.....           Bristol-Myers smashes Q2 as hep C meds rake in overseas sales.....           Forecast-beating Valeant ups 2015 guidance with fast-growing Xifaxan in mind.....           The stichting strikes back: Mylan's Dutch foundation snaps up shares to block Teva buy.....           Novartis whacks 3 Sandoz plants, 770 jobs, despite generic units' sales growth.....           Genmab's partner Novartis submits sBLA to FDA for ofatumumab to treat relapsed CLL.....           Johnson & Johnson to challenge Novartis in axial spondyloarthrtis treatment space, says GlobalData.....           Perrigo agrees to buy German dietary supplement brand Yokebe.....           Medimmune, Sheffield University to research in cell factory technology.....           Pfizer expands lease agreement with Kendall Square for research facility.....           Merck?s Keytruda gets European Commission approval to treat advanced melanoma.....           Ablynx expands immuno-oncology collaboration with Merck.....           Novavax reports positive results from Phase I Ebola GP vaccine trial.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
 
 
Recent meetings

APS Particle Engineering

13 April 2015 - Dublin

The first stage for successful Pharmaceutical formulation

April continued to be a busy month for APS events with a well-attended and successful two-day joint meeting organised with the Synthesis and Solid State Pharmaceutical Centre (SSPC) which brought together many key opinion leaders from academia and industry providing world leading knowledge and case studies in all key aspects around particle engineering.

Read more...

Latest News
APS Summer Student Placement for 2015
TUESDAY, 28 JULY 2015
The APS is pleased to announce the first of the two summer student placements.. This is a new initiative for the APS who working with their focus groups were asked for their interest in participating in a pilot summer student placement scheme to submit a project proposal on a particular topic area they are interested in. A number of high quality proposals were reviewed and two were selected for this year.. . Emma Smith supervised by Dave Berry at Durham University and co-sponsored by the APS Material Science Focus Group. . . . The title of the project is: Comparing the physical properties of racemic and single enantiomer forms of pharmaceutical co-crystals and their glasses. The ambition of the project is to see if there are significant property differences with enantiomeric impurities in co-crystals and if these can be utilised to benefit overall efficiency in drug substance manufacture and efficacy in the drug product.. . The project will involve looking at the difference between bicalutamide R/S and S with some of its co-crystals (nicotinamide/ 2-hydroxybenzamide) to determine if any significant material property differences can be seen when using the racemate and single enantiomer of the drug, both in the crystalline state and in the glass. This will be done with ‘pure’ forms of the enantiomer/racemate as well as with mixtures of differing stoichiometry’s of each 25/75 R to S etc. . This initiative fits well with the APS strategy to raise opportunities for undergraduates and postgraduates, whilst promoting their scientific strategy. . The placement will run for 6-8 weeks and a poster presentation will be given by the student at the PharmSci 2015 meeting in Nottingham. http://www.ukpharmsci.org/default.asp.
Professor Frank Fish Memorial Award Lecture 2015
TUESDAY, 28 JULY 2015
The APS is pleased to support the Professor Frank Fish Memorial Award Lecture 2015. UCL School of Pharmacy Thursday, 15 October 2015 from 17:00 to 19:00 (BST) London, United Kingdom. . The potential and challenge of traditional Chinese medicine to meet unmet clinical needs Professor Tommy (Yung-Chi) Cheng . On Thursday, 15 October 2015 the fourth Frank Fish Memorial lecture entitled 'Potential and challenge of traditional Chinese medicine to meet unmet clinical needs' will be given by Prof. Tommy (Yung-Chi) Cheng from Yale University. We are delighted that a one of the world's leading experts in pharmacology focusing on Traditional Chinese Medicine (TCM) will give this year's lecture.. Time. . 5pm arrivals 5.30pm lecture 6.30pm drinks reception and canapes . Prof. Cheng is Henry Bronson Professor of Pharmacology and the Chairman of the Consortium for the Globalization of Chinese Medicine (CGCM), a network of world-leading universities with an interest in Traditional Chinese Medicine (TCM). In his research he is interested in studying the functional roles and properties of virus-specific proteins in order to design selective antiviral compounds and in exploring the mechanisms of drug resistance development, with a special emphasis on the processes involved in DNA topoisomerase, targeting drugs and nucleoside analogs.. He is particularly well known for his work on PHY906, a TCM preparation composed of four medicinal plants (Scutellaria baicalensis Geori, Glycyrrhiza uralensis Fisch, Paeonia lactiflora Pall and Ziziphus jujube Mill). A combination of these four botanical drugs has been used continuously in TCM for over 1800 years for treating gastrointestinal problems including diarrhoea, nausea, cramps and vomiting. The Professor Frank Fish Memorial Award lectures have been generously funded by Professor Fish's family. Professor Frank Fish was well known in the field of pharmacognosy and phytochemistry, and was Dean at the School of Pharmacy from 1978 - 1988. . For more information, please visit: http://www.eventbrite.co.uk/e/professor-frank-fish-memorial-award-lecture-2015-tickets-17655931366.
Royal Pharmaceutical Society Excellence in Pharmaceutical Science Award
MONDAY, 6 JULY 2015
The APS is delighted to support the following announcement from the RPS:. Royal Pharmaceutical Society 'Excellence in Pharmaceutical Science Award'. Sponsored by Ferring'. The Excellence in Pharmaceutical Science Award recognises pharmaceutical scientists who have delivered proactive and innovative projects and initiatives that lead the way in pharmaceutical science.. Examples of previous submissions and projects that would be suitable for submission for the RPS Excellence in Pharmaceutical Science Award include:. Development of novel sub-unit TB vaccines Technologies for the treatment of brain diseases The design of clinically useful oral chelating agents Development of a delivery vehicle for the treatment of brain diseases Development of a new tuberculosis vaccine Antibiotic dosing in critical care Development of a chip to quantify opiates in a clinical setting Anti-doping project for the London 2012 Olympic and Paralympic games. Do you or a colleague deserve recognition for your work? Nominate today. The deadline for nominations is 9am Monday 20 July.. The awards will be presented at the Royal Pharmaceutical Society Awards Dinner on Sunday 13 September 2015 at the ICC, Birmingham on the evening of the RPS Annual Conference.. http://www.rpharms.com/rps-awards/rps-awards-2015.asp.
APS: CALLING ALL PHARMACY AND PHARMACEUTICAL SCIENCE STUDENTS
MONDAY, 29 JUNE 2015
How will you benefit from attending this year’s APS International PharmSci Conference?. . . The deadline for the early bird rate of 31st July 2015 is fast approaching. Register now to benefit from discounted rates of £66 for one day and up to £170 for three days. Additional discounts are available for APS members.. What APS International PharmSci offers you?. Network with broad range of scientists from fellow students up to eminent professors from most of the key UK Universities. Learn about the latest innovative science by attending a variety of sessions demonstrating how Pharmaceutical Scientists are striving to improve patient health globally http://www.ukpharmsci.org/programme/default.asp. Understand how Pharmaceutical Science is applied in the Industry and what opportunities this might present for you by engaging with representatives from the Pharmaceutical Industry including Pfizer, Astra Zeneca, GSK and BMS.. UK Pharm Sci includes:. A session by the Student Association of the APS (SAPS)on Increasing your employability after your degree. A session by the APS New Scientists Focus Group offering the opportunity for new scientists to present.. Submit an innovative Bright Idea related to the Pharmaceutical Sciences with the chance to win an award of £500 as a contribution to turn the best idea into reality. http://www.ukpharmsci.org/Awards/brightideas.asp. View and discuss posters and hear selected abstracts presented on thepodium. Visit the conference exhibition to see and talk to a range of companies offering the latest testing technologies and learn about career opportunities.. Book now at http://www.ukpharmsci.org/register to be part of this leading Pharmaceutical Sciences Conference and gain an insight into the opportunities within Pharmaceutical Sciences..
 
Follow us
 
Upcoming Events
APS 6th International PharmSci Conference 2015
7 - 9 September 2015
APS Emerging nanomedicine applications in infection, cancer and CNS targeting
10 September 2015
APS 20th Anniversary International Pharmaceutical Photostability Conference 2015
5 - 7 October 2015
APS Board Meeting
13 - 14 October 2015
MIBio 2015: Stability of biopharmaceuticals From molecular interactions to successful products
21 October 2015
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365
Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.